Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation

Background: The recently developed antiandrogen, Enzalutamide (Enz), has reformed the standard of care for castration resistant prostate cancer (CRPC) patients. However, Enz-resistance inevitably emerges despite success of Enz in prolonging CRPC patients’ survival. Here we found that Enz-resistant p...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Hua, Sun, Yin, Huang, Chi-Ping, You, Bosen, Ye, Dingwei, Chang, Chawnshang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226306/
https://www.ncbi.nlm.nih.gov/pubmed/32235588
http://dx.doi.org/10.3390/cancers12040831

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226306/
https://www.ncbi.nlm.nih.gov/pubmed/32235588
http://dx.doi.org/10.3390/cancers12040831

Ejemplares similares